TWYNSTA 40 MG — DIN 02371030
TELMISARTAN : 40 MG AMLODIPINE (AMLODIPINE BESYLATE) : 10 MG · BOEHRINGER INGELHEIM (CANADA) LTD LTEE · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is TWYNSTA?
TWYNSTA 40 MG contains TELMISARTAN : 40 MG AMLODIPINE (AMLODIPINE BESYLATE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02371030, held by BOEHRINGER INGELHEIM (CANADA) LTD LTEE, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 11-Aug-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TWYNSTA used for?
Treatment of mild to moderate essential hypertension for whom combination therapy with telmisartan and amlodipine is appropriate. Not indicated for initial therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Telmisartan And Amlodipine cost around the world?
Telmisartan And Amlodipine is listed on 21 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Spain | PVP con IVA (public price) | 84 | 91 | EUR███.██ |
| Australia | ex-manufacturer | 30 | 88 | AUD███.██ |
| South Africa | single exit price | 76 | 81 | ZAR███.██ |
| Czechia | max producer price (ex-factory) | 20 | 72 | CZK███.██ |
| United States | acquisition | 3 | 62 | USD███.██ |
| Italy | prezzo al pubblico (classe A) | 11 | 31 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 6 | 30 | NOK███.██ |
| Sweden | AIP (pharmacy purchase price) | 9 | 27 | SEK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 26 | 26 | EUR███.██ |
| Luxembourg | reimbursement | 23 | 23 | EUR███.██ |
| Slovakia | categorised final price | 15 | 23 | EUR███.██ |
| Saudi Arabia | public | 12 | 22 | SAR███.██ |
| Bahrain | retail (max) | 10 | 18 | BHD███.██ |
| Hungary | producer price (ex-factory) | 14 | 14 | HUF███.██ |
| United Arab Emirates | public | 13 | 13 | AED███.██ |
| Belgium | public | 8 | 8 | EUR███.██ |
| Romania | max producer price | 7 | 7 | RON███.██ |
| Greece | producer price (ex-factory) | 4 | 4 | EUR███.██ |
| Morocco | PPV (public price) | 1 | 4 | MAD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Iceland | max wholesale | 2 | 2 | ISK███.██ |
649 pack listings across 377 brand entries and 18 price bases, refreshed 08 Sep 2026. Ranges span every Telmisartan And Amlodipine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Telmisartan And Amlodipine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Telmisartan And Amlodipine, across 12 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BOEHRINGER INGELHEIM (CANADA) LTD LTEE | 4 | 4 | TWYNSTA | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 4 | 4 | RIVA-TELMISARTAN/AMLODIPINE | Sourceable in Canada |
| APOTEX INC | 4 | 0 | APO-TELMISARTAN-AMLODIPINE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 40 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Aluminium/aluminium blister cards in cartons of 28 tablets (4 cards of 7 tablets each). |
| Storage | Store at 15-30°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Telmisartan And Amlodipine |
|---|---|
| ATC code | C09DB04 |
| AHFS class | 24:32.08 ; 24:28.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02371030 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2371030 |
| Brand name | TWYNSTA |
| Generic / active ingredient | TELMISARTAN : 40 MG AMLODIPINE (AMLODIPINE BESYLATE) : 10 MG |
| Market authorization holder | BOEHRINGER INGELHEIM (CANADA) LTD LTEE |
| Health Canada schedule | Prescription |
| ATC code | C09DB04 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C09DB |
| Current status | MARKETED |
| Status date | 11-Aug-2011 |
| Original market date | 2011-08-11 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Once daily oral administration. Not for initial therapy. Patients should be titrated on individual drugs before switching to the fixed-dose combination. Swallow whole with liquid.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to ingredients or dihydropyridines; pregnancy/breast-feeding; biliary obstruction; severe hepatic impairment; shock; severe hypotension; left ventricle outflow obstruction.
Warnings and precautions
Fetal toxicity; angioedema (can be fatal); dual blockade of RAS; hypotension in volume/sodium depleted patients; caution in heart failure and aortic/mitral stenosis.
Is Telmisartan And Amlodipine in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SIVEM PHARMACEUTICALS ULC, last seen 13 May 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 12 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| RIVA-TELMISARTAN/AMLODIPINE | 5 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 02559870 |
| RIVA-TELMISARTAN/AMLODIPINE | 10 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 02559862 |
| RIVA-TELMISARTAN/AMLODIPINE | 5 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 02559854 |
| RIVA-TELMISARTAN/AMLODIPINE | 80 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 02559889 |
| TWYNSTA | 5 MG | TABLET | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | MARKETED | 02371022 |
| TWYNSTA | 5 MG | TABLET | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | MARKETED | 02371049 |
| TWYNSTA | 80 MG | TABLET | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | MARKETED | 02371057 |
| APO-TELMISARTAN-AMLODIPINE | 10 MG | TABLET | APOTEX INC | DORMANT | 02473496 |
| APO-TELMISARTAN-AMLODIPINE | 80 MG | TABLET | APOTEX INC | DORMANT | 02473488 |
| APO-TELMISARTAN-AMLODIPINE | 10 MG | TABLET | APOTEX INC | APPROVED | 02473461 |
2 · Same class — other molecules in ATC C09DB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Telmisartan And Amlodipine | APO-TELMISARTAN-AMLODIPINE · RIVA-TELMISARTAN/AMLODIPINE · TWYNSTA | 12 | 8 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C09D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C09DA | Azilsartant Medoximil And Diuretics · Candersartan And Diuretics · Eprosartan And Diuretics · Irbesartan And Diuretics · Losartan And Diuretics · +3 more | 323 | 137 |
| C09DX | Valsartan And Sacubitril | 6 | 6 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is TWYNSTA called?
The same molecule, Telmisartan And Amlodipine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Micardis | Latin | Australia, Bahrain, Czechia, Morocco, Norway |
| MicardisPlus | Latin | Czechia, Norway, Sweden |
| TELMISARTAN/HYDROCHLOROTHIAZID AUXILTO | Latin | Czechia |
| Tolucombi | Latin | Czechia, Norway, Sweden |
| Tolura | Latin | Czechia, Norway, Sweden |
| ARX-Telmisartan/Amlodipine | Latin | Australia |
| Telmisartan/Amlodipine Viatris | Latin | Australia |
| TEZEO HCT | Latin | Czechia |
| Micardis® | Latin | Sweden |
| Telmisartan Sandoz | Latin | Australia, Czechia |
| Telmisartan/HCT Sandoz | Latin | Australia |
| TELMISARTAN/HYDROCHLOROTHIAZID ZENTIVA | Latin | Czechia |
| TEZEFORT | Latin | Czechia |
| APO-Telmisartan | Latin | Australia |
| Dipisar | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.